Exjade and Encephalopathy - a phase IV clinical study of FDA data
Summary:
Encephalopathy is reported as a side effect among people who take Exjade (deferasirox), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Folic Acid, and have Myelodysplastic syndrome.
The phase IV clinical study analyzes which people have Encephalopathy when taking Exjade. It is created by eHealthMe based on reports of 29,418 people who have side effects when taking Exjade from the FDA, and is updated regularly.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
What is Encephalopathy?
Encephalopathy (functioning of the brain is affected by some agent or condition) is found to be associated with 1,467 drugs and 1,602 conditions by eHealthMe. Check the latest studies of Encephalopathy.
29,418 people reported to have side effects when taking Exjade.
Among them, 45 people (0.15%) have Encephalopathy.

Among these 45 people:
How long have people been on Exjade when they have Encephalopathy? *
- < 1 month: 46.67 %
- 1 - 6 months: 40.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 13.33 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Encephalopathy when taking Exjade? *
- female: 54.76 %
- male: 45.24 %
What is the age of people who have Encephalopathy when taking Exjade? *
- 0-1: 0.0 %
- 2-9: 9.68 %
- 10-19: 22.58 %
- 20-29: 6.45 %
- 30-39: 12.9 %
- 40-49: 3.23 %
- 50-59: 6.45 %
- 60+: 38.71 %
What are other drugs people take besides Exjade? *
- Folic Acid: 6 people, 13.33%
- Lasix: 5 people, 11.11%
- Amlodipine: 4 people, 8.89%
- Desferal: 4 people, 8.89%
- Neurontin: 4 people, 8.89%
- Revlimid: 3 people, 6.67%
- Aldactone: 3 people, 6.67%
- Allopurinol: 3 people, 6.67%
- Aspirin: 3 people, 6.67%
- Coreg: 3 people, 6.67%
What are other side effects people have besides Encephalopathy? *
- Fever: 11 people, 24.44%
- Blood Creatinine Increased: 10 people, 22.22%
- Nausea And Vomiting: 10 people, 22.22%
- Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 10 people, 22.22%
- Malaise (a feeling of general discomfort or uneasiness): 9 people, 20.00%
- Weakness: 9 people, 20.00%
- Hepatic Failure (liver failure): 9 people, 20.00%
- Thrombocytopenia (decrease of platelets in blood): 9 people, 20.00%
- Acute Kidney Failure: 9 people, 20.00%
- Sepsis (a severe blood infection that can lead to organ failure and death): 9 people, 20.00%
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 8 people, 17.78%
- High Blood Pressure: 5 people, 11.11%
- Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 6.67%
- Blood Iron Increased: 3 people, 6.67%
- Haemochromatosis (body to absorb more iron than usual from food): 3 people, 6.67%
- Essential Thrombocythaemia (chronic blood cancer): 2 people, 4.44%
- Iron Metabolism Disorder: 2 people, 4.44%
- Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 4.44%
- Pain In Extremity: 2 people, 4.44%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 4.44%
* Approximation only. Some reports may have incomplete information.
Do you take Exjade and have Encephalopathy?
- Check whether Encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Exjade:
- Exjade (29,456 reports)
Encephalopathy treatments and more:
- Encephalopathy (27,832 reports)
How severe was Encephalopathy and when was it recovered:
Expand to all the drugs that have ingredients of deferasirox:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Encephalopathy:
- Encephalopathy (1,467 drugs)
Browse all the conditions that are associated with Encephalopathy:
- Encephalopathy (1,602 conditions)
Related publications that referenced our studies
- Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox (the active ingredients of Exjade) and Exjade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Aricept and Mexitil - a second ago
- Could Benicar cause Dementia With Lewy Bodies? - 13 seconds ago
- Drug interactions of Clemastine Fumarate and Voriconazole - 19 seconds ago
- Drug interactions of Dulcolax and Enzalutamide - 20 seconds ago
- Urination - Painful and Anorexia - 21 seconds ago
- Could Lodine cause Injection Site Swelling? - 24 seconds ago
- Could Intron A cause Nervousness? - 26 seconds ago
- Drug interactions of Magnesium and Ganciclovir Sodium - 28 seconds ago
- Drug interactions of Torsemide and Kisqali - 28 seconds ago
- Could Famotidine cause Hepatic Enzyme Increased? - 29 seconds ago